Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Edward Tenthoff
PIPR
Edward Tenthoff
Wall Street Analyst
★☆☆☆☆
#2532
on 13Foresight · ranked by our own returns
38%
Success Rate
-1.6%
Average Return
24 of 64 calls profitable · -12.0% vs benchmark
📈 Across the calls we could measure, roughly 38% of Edward Tenthoff's ratings turned a profit when each position was held for 1 year — averaging -1.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

148 Buy 2 Hold 1 Sell
Edward's Stock Coverage 73 ratings · 2026-06-19
Company Date Position Consensus Price Target 1-Yr Return
OPK
Opko Health
Jun 17, 2026 BUY Strong Buy
+374.3% avg upside
12 analysts
$3.00
112.84% Upside
·
LEGN
Legend Biotech
Jun 15, 2026 BUY Strong Buy
+134.2% avg upside
27 analysts
$64.00
90.84% Upside
·
NXTC
NextCure
Jun 10, 2026 BUY Buy
+753.8% avg upside
10 analysts
$15.00
581.79% Upside
·
FATE
Fate Therapeutics
Jun 09, 2026 BUY Buy
+492.3% avg upside
31 analysts
$6.00
206.06% Upside
·
IPSC
Century Therapeutics
Jun 09, 2026 BUY Strong Buy
+132.9% avg upside
11 analysts
$4.00
77.80% Upside
+4.5%
BMEA
Biomea Fusion
Jun 09, 2026 BUY Strong Buy
+1034.7% avg upside
15 analysts
$7.00
483.43% Upside
·
ARVN
Arvinas Holding Company
Jun 03, 2026 BUY Buy
+265.4% avg upside
27 analysts
$20.00
160.78% Upside
-1.6%
FULC
Fulcrum Therapeutics
Jun 02, 2026 SELL Hold
+138.8% avg upside
13 analysts
$3.00
14.25% Downside
·
IBRX
ImmunityBio
Jun 01, 2026 BUY Strong Buy
+55.2% avg upside
12 analysts
$12.00
71.62% Upside
·
INO
Inovio Pharmaceuticals
May 22, 2026 BUY Buy
+808.5% avg upside
19 analysts
$6.00
440.60% Upside
-18.5%
CAMP
CAMP4 Therapeutics Corporation
May 15, 2026 BUY Strong Buy
+131.4% avg upside
9 analysts
$12.00
189.95% Upside
+3.2%
CRDF
Cardiff Oncology
May 15, 2026 BUY Strong Buy
+736.8% avg upside
18 analysts
$6.00
408.57% Upside
+0.0%
DYN
Dyne Therapeutics
May 14, 2026 BUY Strong Buy
+93.5% avg upside
29 analysts
$45.00
134.40% Upside
+8.3%
MIST
Milestone Pharmaceuticals
May 14, 2026 BUY Strong Buy
+536.3% avg upside
7 analysts
$7.00
434.41% Upside
-10.1%
CAPR
Capricor Therapeutics
May 13, 2026 BUY Strong Buy
+68.4% avg upside
12 analysts
$58.00
107.45% Upside
-5.1%
SKYE
Skye Bioscience
May 12, 2026 BUY Strong Buy
+1336.8% avg upside
9 analysts
$6.00
743.33% Upside
+0.0%
XNCR
Xencor
May 08, 2026 BUY Strong Buy
+159.5% avg upside
27 analysts
$33.00
158.29% Upside
-12.4%
GENB
Generate Biomedicines, Inc.
May 08, 2026 BUY Strong Buy
+76.8% avg upside
6 analysts
$24.00
72.98% Upside
·
GLUE
Monte Rosa Therapeutics
May 08, 2026 BUY Strong Buy
+27.3% avg upside
14 analysts
$37.00
101.05% Upside
-5.6%
MRNA
Moderna
May 08, 2026 BUY Hold
+6.4% avg upside
38 analysts
$69.00
11.64% Upside
+17.7%
CTMX
CytomX Therapeutics
May 08, 2026 BUY Strong Buy
+269.4% avg upside
21 analysts
$12.00
305.39% Upside
-24.4%
ARWR
Arrowhead Pharmaceuticals
May 08, 2026 BUY Strong Buy
-19.1% avg upside
26 analysts
$110.00
35.67% Upside
+2.5%
CRSP
Crispr Therapeutics AG
May 05, 2026 BUY Buy
+39.7% avg upside
41 analysts
$110.00
107.29% Upside
-0.7%
ALNY
Alnylam Pharma
May 01, 2026 BUY Strong Buy
+23.4% avg upside
51 analysts
$489.00
72.99% Upside
-4.5%
KPTI
Karyopharm Therapeutics
Apr 27, 2026 BUY Strong Buy
+146.1% avg upside
18 analysts
$16.00
70.18% Upside
-11.4%
MESO
Mesoblast
Apr 10, 2026 BUY Strong Buy
+73.3% avg upside
14 analysts
$35.00
150.44% Upside
-1.4%
ACRV
Acrivon Therapeutics, Inc.
Mar 02, 2026 BUY Strong Buy
+818.9% avg upside
13 analysts
$8.00
426.26% Upside
+15.7%
MCRB
Seres Therapeutics
Feb 13, 2026 HOLD Buy
+163.4% avg upside
10 analysts
$20.00
209.63% Upside
-10.4%
KYMR
Kymera Therapeutics
Dec 09, 2025 BUY Strong Buy
+9.0% avg upside
36 analysts
$125.00
39.03% Upside
+3.5%
STRO
Sutro Biopharma
Dec 04, 2025 BUY Strong Buy
+31.8% avg upside
20 analysts
$20.00
29.63% Downside
+207.0%
CUE
Cue Biopharma
Apr 01, 2025 BUY Strong Buy
-66.0% avg upside
9 analysts
$2.00
92.48% Downside
-72.9%
TPST
Tempest Therapeutics
Mar 28, 2025 BUY Buy
+1662.1% avg upside
18 analysts
$65.00
5100.01% Upside
-82.8%
XFOR
X4 Pharmaceuticals
Feb 07, 2025 BUY Strong Buy
+496.4% avg upside
15 analysts
$60.00
1381.52% Upside
-77.6%
SYRS
Syros Pharmaceuticals
Oct 23, 2024 BUY Buy
+10812400.0% avg upside
9 analysts
$5.00
1249900.01% Upside
-100.0%
TSE:APS
Aptose Biosciences
Apr 03, 2024 BUY Strong Buy
+4059.2% avg upside
10 analysts
$209.96
9443.38% Upside
·
BCYC
Bicycle Therapeutics
Nov 03, 2023 BUY Strong Buy
+504.5% avg upside
20 analysts
$52.00
1187.08% Upside
+46.2%
GRTX
Galera Therapeutics
Aug 17, 2023 HOLD Buy
+6826.8% avg upside
7 analysts
$0.50
488.29% Upside
·
ATYR
aTyr Pharma
Apr 11, 2023 BUY Buy
+2016.8% avg upside
17 analysts
$13.00
2708.40% Upside
-11.6%
INFIQ
Infinity Pharmaceuticals
Feb 23, 2023 HOLD Buy
+647142757.1% avg upside
8 analysts
$0.30
29999900.00% Upside
-100.0%
SYRE
Spyre Therapeutics
Oct 27, 2022 BUY Strong Buy
-15.4% avg upside
23 analysts
$37.50
57.14% Downside
·
PRTCY
PureTech Health
Aug 25, 2022 BUY Strong Buy
+194.2% avg upside
3 analysts
$44.00
153.75% Upside
·
APVO
Aptevo Therapeutics
Aug 12, 2022 BUY Strong Buy
+163.1% avg upside
4 analysts
$13.00
170.77% Upside
-89.4%
ELOX
Eloxx Pharmaceuticals
May 23, 2022 BUY Strong Buy
+153.9% avg upside
8 analysts
$60.00
328.64% Upside
-37.8%
KLDO
Kaleido Biosciences
Jan 30, 2022 BUY Buy
+13249900.0% avg upside
5 analysts
$4.00
3999900.03% Upside
·
VRTX
Vertex Pharmaceuticals
Oct 18, 2021 BUY Strong Buy
-2.7% avg upside
61 analysts
$323.00
29.58% Downside
+66.0%
SYBX
Synlogic
Sep 20, 2021 BUY Buy
+3290.3% avg upside
11 analysts
$9.00
1167.65% Upside
-72.2%
CYTK
Cytokinetics
Aug 08, 2021 BUY Strong Buy
+8.9% avg upside
36 analysts
$40.00
48.70% Downside
+67.9%
EXEL
Exelixis
Jun 28, 2021 BUY Strong Buy
-21.1% avg upside
33 analysts
$36.00
31.36% Downside
+16.2%
ARGX
Argenx Se
Jun 07, 2021 HOLD Strong Buy
-15.8% avg upside
46 analysts
$250.00
71.94% Downside
+25.1%
GB:0QW0
arGEN X
Feb 04, 2021 HOLD Strong Buy
-23.2% avg upside
24 analysts
$266.08
65.36% Downside
·
MTNB
Matinas BioPharma
Jun 30, 2020 BUY Buy
+2183.8% avg upside
7 analysts
$1.50
111.20% Upside
+0.3%
MRKR
Marker Therapeutics
May 12, 2020 HOLD Strong Buy
+994.1% avg upside
9 analysts
$2.50
85.22% Upside
-8.5%
GILD
Gilead Sciences
Mar 20, 2020 BUY Strong Buy
-4.8% avg upside
66 analysts
$90.00
28.27% Downside
-8.2%
CFRXQ
ContraFect
Dec 11, 2019 BUY Buy
+10969999900.0% avg upside
10 analysts
$10.00
999999899.98% Upside
·
LRMR
Larimar Therapeutics
Sep 05, 2019 HOLD Strong Buy
+413.5% avg upside
21 analysts
$60.00
1594.85% Upside
+45.8%
SRPT
Sarepta Therapeutics
Jun 21, 2019 BUY Buy
+246.5% avg upside
49 analysts
$208.00
1126.39% Upside
+30.0%
BAYRY
Bayer
Jun 04, 2019 BUY Buy
+293.3% avg upside
9 analysts
$32.00
198.71% Upside
+21.6%
NVAX
Novavax
Feb 28, 2019 SELL Buy
+154.0% avg upside
20 analysts
$5.00
47.31% Downside
-12.7%
ONCSQ
OncoSec Medical
Dec 12, 2018 BUY Strong Buy
+4699999900.0% avg upside
9 analysts
$30.00
2999999899.99% Upside
·
VCEL
Vericel
Nov 06, 2018 BUY Strong Buy
+14.1% avg upside
16 analysts
$19.00
51.37% Downside
+12.6%
VTAK
Catheter Precision
Oct 22, 2018 BUY Buy
+2677.9% avg upside
5 analysts
$23.00
2320.99% Upside
-87.8%
ANTH
Anthera Pharmaceuticals
Mar 12, 2018 SELL Buy
+472857042.9% avg upside
9 analysts
$0.10
9999899.92% Upside
·
GNCAQ
Genocea Biosciences
Nov 02, 2017 BUY Strong Buy
+573999900.0% avg upside
10 analysts
$5.00
499999899.95% Upside
·
REGN
Regeneron
Sep 11, 2017 BUY Strong Buy
+26.9% avg upside
57 analysts
$557.00
8.37% Downside
-11.5%
VIVS
VivoSim Labs
Feb 09, 2017 BUY Buy
+156.6% avg upside
5 analysts
$4.00
254.02% Upside
-67.4%
SVRA
Savara
Sep 07, 2016 BUY Strong Buy
+58.2% avg upside
17 analysts
$1.00
81.38% Downside
-26.4%
DAL
Delta Air Lines
Aug 18, 2016 BUY Strong Buy
-10.3% avg upside
30 analysts
$35.00
57.42% Downside
+29.8%
XOMA
XOMA Royalty Corporation
Mar 10, 2016 HOLD Buy
-46.4% avg upside
11 analysts
-68.5%
ATHXQ
Athersys
Jul 09, 2015 HOLD Buy
+29964185.8% avg upside
8 analysts
$1.00
999900.05% Upside
+99.1%
IONS
Ionis Pharmaceuticals
Jul 23, 2013 SELL Strong Buy
+13.3% avg upside
43 analysts
$20.00
73.04% Downside
-7.8%
ONCY
Oncolytics Biotech
Mar 04, 2013 BUY Strong Buy
+654.5% avg upside
12 analysts
$6.00
544.00% Upside
-49.0%
CRIS
Curis
Feb 20, 2013 BUY Strong Buy
+1938.0% avg upside
12 analysts
$6.00
1377.82% Upside
+13.5%
SLS
SELLAS Life Sciences Group
Dec 31, 2012 BUY Strong Buy
+768.3% avg upside
15 analysts
$2.50
67.87% Downside
+224.2%
🔒 68 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Edward Tenthoff — Frequently Asked Questions
How accurate are Edward Tenthoff's stock ratings?
Based on the calls 13Foresight could measure, about 36% of Edward's ratings were profitable over a one-year hold, with an average return of -2.0% per rating, or -12.4% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Edward ranked on 13Foresight?
Edward Tenthoff is currently ranked #2532 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Edward cover?
Edward most recently has ratings on OPK, LEGN, NXTC, FATE, IPSC, BMEA, ARVN, FULC, IBRX, INO, CAMP, CRDF and 61 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.